lighthouse concept.
In the LightHouse concept (Figure 1), 99Mo is produced by irradiating the non-radioactive 100Mo with an intense electron beam. Compared to nuclear production, this alternative is, in principle, reliable and cheaper, requires no radioactive uranium and produces hardly any waste. In addition, the technique is capable of producing quantities comparable to those produced by a nuclear reactor. Electron accelerators are already used to produce small quantities of low-specific-activity 99Mo, but this does not meet the specifications for large-scale production of 99Mo for nuclear medicine. That requires a superconducting, high-power linear electron accelerator. The electron beam it produces is split into two to expose a target composed of 100Mo-enriched molybdenum from both sides, to achieve a relatively uniform activation profile. The high-energy electrons are stopped in the target, which produces Bremsstrahlung (high-energy gamma rays) that transforms the 100Mo into 99Mo. After irradiation, the 99Mo is harvested from the target.
The LightHouse concept poses big physical and technical challenges. Therefore, financially supported by the Belgian authorities, IRE, with the technical support of ASML, integrated the LightHouse technology in the SMART project (Source of MedicAl RadioisoTopes), in which over 25 research institutes and high-tech companies participate. The various production components of the future LightHouse facility are developed by specialists. Research Instruments, based in Bergisch Gladbach (Germany), is an expert in the field of particle accelerators, while Demcon is developing the exposure unit, including the target, and the harvesting unit.